Equity Profile

ALNY

Alnylam Pharmaceuticals, Inc.

Health CareBiotechnology$30.4B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps gauge the company's financial performance.

$2.22

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$1.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ALNY Q2-2026 Earnings Preview

Context

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference. With a market cap of $30 billion, it plays a significant role in the health care sector, particularly in innovative treatments for genetic diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+157.23%

Avg Stock Reaction

+1.45%

Last Quarter Recap

In Q1-2026, Alnylam reported an EPS of $1.99, significantly exceeding expectations, which led to a positive market reaction. However, revenue details were not disclosed.

Management Promises & Guidance

Continued focus on advancing RNAi therapies.
Commitment to expanding market presence.
Plans to enhance product pipeline.

Expectations

Wall Street Expectations

Analysts are optimistic about Alnylam's upcoming earnings, expecting strong EPS and revenue growth. The company has a track record of beating earnings estimates, which adds to positive sentiment.

Bull Case

If Alnylam can deliver EPS above $2.22 and revenue at or above $1.5 billion, it could reinforce confidence in its growth trajectory and boost stock prices.

Bear Case

Conversely, if the company fails to meet these expectations, particularly after its recent strong performance, it could lead to a significant sell-off.

Key Metrics to Watch

EPS

$2.22

Earnings per share is a key indicator of profitability and helps gauge the company's financial performance.

Revenue

$1.5B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Alnylam's EPS exceed the consensus estimate of $2.22?

A beat on EPS would reinforce the company's strong performance trend and could drive the stock higher.

What specific revenue figures can Alnylam provide for Q2-2026?

Clear revenue guidance will help investors assess the company's growth and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Alnylam's revenue potential due to strong demand for its therapies, which could lead to a significant upside surprise.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a strong operational performance.

Options pricing indicates a larger move than historical averages, reflecting investor uncertainty.

Recent developments in RNAi therapies may not be fully reflected in analyst expectations.

Key Risk

If Alnylam's revenue exceeds $1.6 billion, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Alnylam's ability to sustain its recent earnings momentum and revenue growth.

Bull Confirmed If

An EPS of $2.50 or higher would confirm the bullish outlook.

Bear Confirmed If

An EPS below $1.94 would indicate a bearish trend.

Pre-Earnings Positioning

Options Market

Implied Move

±19.80%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a significant potential price movement following the earnings report, indicating heightened investor uncertainty.

Options are pricing ±19.8% while ALNY has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

30.3%

Calls (21K)P/C Ratio: 0.89Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Alnylam beats expectations, history suggests a potential stock increase of around 1.45% on the following day, confirming the positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 6.38%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiency.
4Guidance on future revenue expectations and growth strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps gauge the company's financial performance.

$2.22

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$1.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ALNY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+157.23%

Avg Stock Reaction

+1.45%

Last Quarter Recap

In Q1-2026, Alnylam reported an EPS of $1.99, significantly exceeding expectations, which led to a positive market reaction. However, revenue details were not disclosed.

Management Promises & Guidance

Continued focus on advancing RNAi therapies.
Commitment to expanding market presence.
Plans to enhance product pipeline.

Expectations

Wall Street Expectations

Analysts are optimistic about Alnylam's upcoming earnings, expecting strong EPS and revenue growth. The company has a track record of beating earnings estimates, which adds to positive sentiment.

Bull Case

If Alnylam can deliver EPS above $2.22 and revenue at or above $1.5 billion, it could reinforce confidence in its growth trajectory and boost stock prices.

Bear Case

Conversely, if the company fails to meet these expectations, particularly after its recent strong performance, it could lead to a significant sell-off.

Key Metrics to Watch

EPS

$2.22

Earnings per share is a key indicator of profitability and helps gauge the company's financial performance.

Revenue

$1.5B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Alnylam's EPS exceed the consensus estimate of $2.22?

A beat on EPS would reinforce the company's strong performance trend and could drive the stock higher.

What specific revenue figures can Alnylam provide for Q2-2026?

Clear revenue guidance will help investors assess the company's growth and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Alnylam's revenue potential due to strong demand for its therapies, which could lead to a significant upside surprise.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a strong operational performance.

Options pricing indicates a larger move than historical averages, reflecting investor uncertainty.

Recent developments in RNAi therapies may not be fully reflected in analyst expectations.

Key Risk

If Alnylam's revenue exceeds $1.6 billion, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Alnylam's ability to sustain its recent earnings momentum and revenue growth.

Bull Confirmed If

An EPS of $2.50 or higher would confirm the bullish outlook.

Bear Confirmed If

An EPS below $1.94 would indicate a bearish trend.

Pre-Earnings Positioning

Options Market

Implied Move

±19.80%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a significant potential price movement following the earnings report, indicating heightened investor uncertainty.

Options are pricing ±19.8% while ALNY has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

30.3%

Calls (21K)P/C Ratio: 0.89Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Alnylam beats expectations, history suggests a potential stock increase of around 1.45% on the following day, confirming the positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 6.38%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market demand and competitive landscape.
3Insights into cost management and operational efficiency.
4Guidance on future revenue expectations and growth strategies.